Cristcot LLC

CONCORD, MA · Founded 2015 · Biotech · Private

Drug formulations and integrated drug-device technologies for improved patient adherence and disease management

Claim this profile

Follows are private to you and power your alerts

Updated · cristcot.com

Sector
Biotech
Headquarters
CONCORD, MA
Founded
2015
Latest Form D
$10.5M, Jun 2025
Total capital
$20.9M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$20.9M
4 Form D · last Jun 2025
17 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
16
12 pending · first 2017
Rank in peer group#105 of 1449

Capital timeline

20172019202120232025FEDERAL ↑EQUITY ↓Cumulative $20.9M1st Form D$411K2nd Form D$3M3rd Form D$7M
20172019202120232025FEDERAL ↑EQUITY ↓Cumulative $20.9M2nd Form D$3M3rd Form D$7M

Latest events

  • Private capital raisedForm D · SEC · 4th filing$10.5M
  • Private capital raisedForm D · SEC · 3rd filing$7M
  • Private capital raisedForm D · SEC · 2nd filing$3M
  • Private capital raisedForm D · SEC · 1st filing$411K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#105 · top 7%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Jennifer J. DavagianResearcherExecutive Officer, DirectorLinked by 14 patents
  • David H. ShepardDirectorNamed in SEC Form D filings
  • David H. ShepherdDirectorNamed in SEC Form D filings
  • Ernest H. PomerantzDirectorNamed in SEC Form D filings
  • Henry S. KayDirectorNamed in SEC Form D filings
  • James Davagian BartlettDirectorNamed in SEC Form D filings
Show all 12 people
  • Jennifer Davagian EnsignExecutive Officer, DirectorNamed in SEC Form D filings
  • John H. DavagianDirectorNamed in SEC Form D filings
  • John S. Davagian IIDirectorNamed in SEC Form D filings
  • Marc S. KellerDirectorNamed in SEC Form D filings
  • Mark C. EnsignExecutive OfficerNamed in SEC Form D filings
  • Richard H. WarburgDirectorNamed in SEC Form D filings

What it has protected

USPTO · 16 granted of 28
  • PendingMethods Of Treating Gastrointestinal Diseases And DisordersUSPTOApplication 19286557
  • GrantedMethods Of Treating Gastrointestinal Diseases And DisordersUSPTOUS 12,396,946
  • PendingSuppository Insertion Device, Suppository, And Method Of Manufacturing A SuppositoryUSPTOApplication 19081297
Show all 28 patent records

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .